Cambridge Healthtech Institute’s Inaugural
Advances in Purification Technologies
Advanced Technologies and Novel Concepts in Protein Purification
Part of CHI's 6th Annual The Bioprocessing Summit

August 21-22, 2014 | Renaissance Waterfront Hotel | Boston, Massachusetts

While upstream process scientists are churning out higher and higher titers, downstream process engineers have been busy with developing possible solutions to ameliorate the bottlenecks, increase productivity while lowering cost. Some of these technological advances are novel concepts while others are radical advances that push the envelopes. CHI’s Advances in Purification Technologies conference offers insights into the exciting world of purification driven by developments in chromatography, crystallization, precipitation, filtration and clarification. This is a platform for you and your colleagues to come together to exchange ideas and review the innovations in downstream purification.

Fast-track your learning objectives by attending the co-located Short Course on ABC: Anything but Chromatography – Precipitation, Crystallization and Flocculation. This 3-hour dinner short course is conducted by Dr. Alois Jungbauer of BOKU to help you overcome productivity limits and design a cost-effective scalable process.

Day 1 | Day 2 | Short Courses | Download Brochure | Speaker Bios 

Thursday, August 21

1:55 pm Chairperson’s Remarks

Greg Zarbis-PapastoitsisGreg Zarbis-Papastoitsis, Ph.D., Vice President, Process and Manufacturing Sciences, Eleven Biotherapeutics


Cold Ethanol Precipitation and Flocculation for Continuous Downstream Processing of Recombinant Antibodies

Alois JungbaerAlois Jungbauer, Ph.D., Professor, Department of Biotechnology, University of Natural Resources and Life Science Vienna, (BOKU) and Austrian Centre of Industrial Biotechnology

We have developed a completely new, non-chromatographic alternative based on a series of selective precipitation and flocculation steps. Our process does not need elution chromatography anymore. The method is a generic platform technology and has been tested in the purification of several human antibodies with different pI and hydrophobicity. The full potential of this new continuous downstream technology can be harnessed by coupling to a continuous upstream process/perfusion reactor. Examples for fully continuous operating reactors will be shown.


2:45 Dramatic Improvements in Process Economy with Non-Column Purification

Richard NianRichard Nian, Ph.D., Research Scientist, Downstream Processing Group, Bioprocess Technology Institute, A*Star, Singapore

In this study, we show data from new clarification methods that enable a number of non-protein A capture alternatives, including non-column formats. We also show data from a breakthrough convection-based system that supports 10-fold lower host protein, aggregate and DNA content, plus 10-20% higher IgG recovery compared to 3-step protein A platforms. And it achieves these results with two thirds less water than current protein A platforms.

3:15 A Designed Calcium-Responsive Peptide Domain for Non-Chromatographic Protein Purification

Scott Banta, Ph.D., Associate Professor, Chemical Engineering, Columbia University

We have discovered a peptide sequence based on the beta-roll forming RTX domain that reversibly precipitates in the presence of calcium. We have developed this phase-change as a simple method for the non-chromatographic purification of recombinant proteins. We have demonstrated this technique with several model proteins, and the technique should be broadly applicable.

3:45 Implementing 45 cm ID Pre-Packed Columns for GMP Manufacturing

Malcom_FletcherFletcher Malcom, MBA, Associate Director, Product Management, Repligen Corporation

Implementation of pre-packed disposable columns is increasing as the technology advances to deliver more options for GMP manufacturing operations which rely on disposable components. This presentation explores the new technological developments as well as the benefits of larger 45 cm ID pre-packed chromatography columns.

4:00 Refreshment Break in the Exhibit Hall with Poster Viewing

4:45 Breakout Discussions

This session provides the opportunity to discuss a focused topic with peers from around the world in an open, collegial setting. Select from the list of topics available and join the moderated discussion to share ideas, gain insights, establish collaborations or commiserate about persistent challenges. At the end of the session, each moderator will summarize the topics being discussed, the findings and conclusions (if any), and share with the audience.

Topics include:

Alternatives to Protein A

Moderator: Greg Zarbis-Papastoitsis, Ph.D., Vice President, Process and Manufacturing Sciences, Eleven Biotherapeutics

• Is there a “cheaper” Protein A resin a reasonable expectation?
• Can smaller and higher capacity Protein A columns/resins do the trick?
• Revisiting “older” technologies, such as precipitation/phase extraction, can they become platform technologies for Mabs and alternatives to Protein A?
• Is there really an issue with using Protein A as is?



Continuous Downstream Processes

Moderator: Andrew Zydney, Ph.D., Professor and Department Head, Chemistry Engineering, The Pennsylvania State University
• Numerous companies are pursuing continuous bioreactors (e.g., perfusion bioreactors)
• What are the key barriers to implementing continuous downstream processes?
• What are the key technology challenges that must be overcome?

Non-Traditional Recombinant Protein Purification

Moderator: Yingxia Wen, Ph.D., Head of Laboratory, Novartis Vaccines & Diagnostics

• Possibility to build purification platform for non-traditional recombinant protein.
• Separation of protein with aggregration.
• Prevention of enzymatic protein cleavage.

Strategies for Non-Chromatographic Bioseparations

Moderator: Scott Banta, Ph.D., Associate Professor, Chemical Engineering, Columbia University

• There has been interest in developing purification tags for recombinant proteins
• What are the challenges in developing and utilizing these strategies?
• What has limited this approach so far?
• What is needed to enable large-scale non-chromatographic purification of recombinant proteins?  

Viral Clearance Strategies for Biopharmaceuticals

Joe Zhou, Ph.D., CEO, Genor Biopharma, Walvax Bio Group and Visiting Professor, Peking University 


Process Economy with Non-Column Chromatography

Richard Nian, Ph.D., Research Scientist, Downstream Processing Group, Bioprocess Technology Institute, A*Star, Singapore

5:45 End of Day

Suggested Short Course*

5:45 – 6:30 Dinner Short Course Registration

6:30 – 9:00 Dinner Short Course*: ABC: Anything But Chromatography – Precipitation, Crystallization and Flocculation 

*Separate registration required

Day 1 | Day 2 | Short Courses | Download Brochure | Speaker Bios 


Premier Sponsors:


Millipore Sigma

Unchained Labs